Evidence map›Paper›PMID 38796651›Full record

ArticleMolecular biology reports2024

Alternations in miR-155 and miR-200 serum levels can serve as biomarkers for COVID-19 in the post-mass vaccination era.

Aliaa Aboulela, Mona Taha, Abeer Ghazal, Ayman Baess, Amel Elsheredy

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Aliaa AboulelaMedical Research Institute, Microbiology Department, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-2923-1027
Mona TahaMedical Research Institute, Microbiology Department, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0003-0648-4694
Abeer GhazalMedical Research Institute, Microbiology Department, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0001-8530-4879
Ayman BaessFaculty of Medicine, Chest Diseases Department, Alexandria University, Alexandria, Egypt.ORCID https://orcid.org/0000-0002-4297-8061
Amel ElsheredyMedical Research Institute, Microbiology Department, Alexandria University, Alexandria, Egypt. amel.elsheredy@alexu.edu.eg.ORCID https://orcid.org/0000-0001-6368-2596

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMass vaccination and natural immunity reduced the severity of COVID-19 cases. SARS-CoV-2 ongoing genome variations imply the use of confirmatory serologic biomarkers besides PCR for reliable diagnosis. MicroRNA molecules are intrinsic components of the innate immune system. The expression of miR155-5p and miR200c-3p was previously correlated with SARS-CoV-2 pathogenesis. This case-control study was conducted during the third peak of the COVID-19 pandemic in Egypt and aimed to calculate the accuracy of miR155-5p and miR200c-3p as biomarkers for COVID-19. METHODS AND

resultsThirty out of 400 COVID-19 patients at a main University hospital in Alexandria were included in the study along with 20 age-matched healthy controls. Plasma samples were collected for total and differential CBC. Relative quantitation of miR155-5p and miR200c-3p expression from WBCs was done by RT-qPCR. The expression of miR155-5p and miR200c-3p was positively correlated and was significantly downregulated in COVID-19 patients compared to the healthy control group (p ˂ 0.005). Both miR155-5p and miR200c-3p were of 76% and 74% accuracy as diagnostic biomarkers of COVID-19, respectively. Regarding the differentiation between mild and moderate cases, their accuracy was 80% and 70%, respectively.

conclusionsmiR155-5p and miR200c-3p expression can be used to confirm the diagnosis of COVID-19 and discriminate between mild and moderate cases, with a moderate degree of accuracy.

Indexed as

BiomarkersCOVID-19MicroRNAsSARS-CoV-2AdultCase-Control StudiesEgyptFemaleHumansMaleMiddle AgedBiomarkersMicroRNAsMIRN100 microRNA, humanMIRN155 microRNA, humanCOVID-19Immune responsemiR155-5pmiR200c-3pmiRNA biomarkersSARS-CoV-2 post mass-vaccination

Identifiers

PMID38796651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.